Cytokeratin immunohistochemistry improves interobserver variability between unskilled pathologists in the evaluation of tumor budding in T1 colorectal cancer

Tumor budding is a major risk factor for T1 colorectal cancer. Quality control of the pathological diagnosis of budding is crucial, irrespective of the pathologist's experience. This study examines the interobserver variability according to pathologists' experience and evaluates the influence of cytokeratin (CK) immunostaining in the assessment of budding. Hematoxylin‐eosin (HE) and CK‐immunostained slides of 40 cases with T1 primary colorectal cancer were examined. Budding grades were individually evaluated by 12 pathologists who we categorized into three groups by their experience (expert, with >10 years of experience (n = 4), senior, with 5–10 years (n = 4), and junior, < 5 years (n = 4)). The results revealed a tendency for the more experienced pathologists to assign higher budding grades compared to the less‐experienced pathologists. In the junior group, the interobserver variability obtained with HE slides was poor, but it was markedly improved in the evaluation using CK‐immunostained slides. The benefit of CK immunostaining was only slight in the expert group. CK immunostaining would be useful when a pathologist is not experienced enough or does not have enough confidence in the assessment of budding.

[1]  Giovanni Ponti,et al.  Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma. , 2006, Pathology, research and practice.

[2]  J. O’Sullivan,et al.  Tumor Budding is a Strong and Reproducible Prognostic Marker in T3N0 Colorectal Cancer , 2009, The American journal of surgical pathology.

[3]  S. Sarıoğlu,et al.  Tumor budding as a prognostic marker in laryngeal carcinoma. , 2010, Pathology, research and practice.

[4]  H. Ueno,et al.  Indicators for treatment strategies of colorectal liver metastases. , 2000, Annals of Surgery.

[5]  H. Ueno,et al.  Differential Prognostic Significance of Morphologic Invasive Markers in Colorectal Cancer: Tumor Budding and Cytoplasmic Podia , 2006, Diseases of the colon and rectum.

[6]  F. Prall.  Tumour budding in colorectal carcinoma , 2007, Histopathology.

[7]  H. Ueno,et al.  Histologic indices in biopsy specimens for estimating the probability of extended local spread in patients with rectal carcinoma , 2002, Cancer.

[8]  H. Ueno,et al.  A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo‐fragments around budding foci , 2005, Histopathology.

[9]  H. Ueno,et al.  Tumour `budding' as an index to estimate the potential of aggressiveness in rectal cancer , 2002, Histopathology.

[10]  Takatoshi Nakamura,et al.  Diagnostic reproducibility of tumour budding in colorectal cancer: a multicentre, multinational study using virtual microscopy , 2012, Histopathology.

[11]  M. Oya,et al.  Budding as a useful prognostic marker in pT3 well‐ or moderately‐differentiated rectal adenocarcinoma , 2003, Journal of surgical oncology.

[12]  F. Offner,et al.  Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study , 2015, Virchows Archiv.

[13]  H. Ueno,et al.  A New Prognostic Staging System for Rectal Cancer , 2004, Annals of surgery.

[14]  Y. Kodera,et al.  Multivariate Analysis of the Pathologic Features of Esophageal Squamous Cell Cancer: Tumor Budding Is a Significant Independent Prognostic Factor , 2008, Annals of Surgical Oncology.

[15]  M. Morimatsu,et al.  An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer , 1989, Cancer.

[16]  M. Roh,et al.  Tumor budding as a prognostic marker in stage-III rectal carcinoma , 2007, International Journal of Colorectal Disease.

[17]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.

[18]  H. Nagawa,et al.  Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2 , 2006, British Journal of Cancer.

[19]  L. Terracciano,et al.  Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. , 2013, Human pathology.

[20]  S. Kalloger,et al.  Tumor Budding Is an Independent Adverse Prognostic Factor in Pancreatic Ductal Adenocarcinoma , 2015, The American journal of surgical pathology.

[21]  H E Gabbert,et al.  Tumor‐cell dissociation at the invasion front: A new prognostic parameter in gastric cancer patients , 1992, International journal of cancer.

[22]  K. Hase,et al.  Prognostic value of tumor “budding” in patients with colorectal cancer , 1993, Diseases of the colon and rectum.

[23]  L. Mazzucchelli,et al.  Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. , 2010, World journal of gastroenterology.

[24]  C. Ostwald,et al.  High-degree tumor budding and podia-formation in sporadic colorectal carcinomas with K-ras gene mutations. , 2007, Human pathology.

[25]  R. Riddell,et al.  Tumor budding in colorectal carcinoma: time to take notice , 2012, Modern Pathology.

[26]  L. Terracciano,et al.  CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour’ approach to tumour host interaction in colorectal cancer , 2009, British Journal of Cancer.

[27]  R. Swindell,et al.  Tumour budding and a low host inflammatory response are associated with a poor prognosis in oesophageal and gastro‐oesophageal junction cancers , 2010, Histopathology.

[28]  Hidetaka Mochizuki,et al.  Risk factors for an adverse outcome in early invasive colorectal carcinoma. , 2004, Gastroenterology.

[29]  K. Togashi,et al.  Evaluation of Venous Invasion by Elastica van Gieson Stain and Tumor Budding Predicts Local and Distant Metastases in Patients With T1 Stage Colorectal Cancer , 2009, The American journal of surgical pathology.

[30]  Toshiaki Watanabe.  The Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (The 49th annual meeting of Japanese Society of Clinical Oncology educational book) -- (JSCO University: Colorectal cancers) , 2011 .

[31]  E. Patsouris,et al.  Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer , 2013, Modern Pathology.

[32]  Y. Akasaka,et al.  Histopathologic determinants of regional lymph node metastasis in early colorectal cancer , 2008, Cancer.

[33]  D. Marchant,et al.  Risk factors. , 1994, Obstetrics and gynecology clinics of North America.

[34]  A. Nonomura,et al.  Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. , 2008, Anticancer research.

[35]  M. Barten,et al.  Tumour budding as prognostic factor in stage I/II colorectal carcinoma , 2005, Histopathology.

[36]  C. Rubio,et al.  Tumour budding correlates with local recurrence of rectal cancer , 2011, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[37]  R. Moll,et al.  Tumor dedifferentiation: An important step in tumor invasion , 1985, Clinical & Experimental Metastasis.

[38]  K. Sheahan,et al.  Reproducibility of the rapid bud count method for assessment of tumor budding in stage II colorectal cancer. , 2010, The American journal of surgical pathology.

[39]  M. Oya,et al.  Budding as a Risk Factor for Lymph Node Metastasis in pT1 or pT2 Well-Differentiated Colorectal Adenocarcinoma , 2002, Diseases of the colon and rectum.

[40]  K. Miyazaki,et al.  Tumor budding and dedifferentiation in gallbladder carcinoma: potential for the prognostic factors in T2 lesions , 2011, Virchows Archiv.